Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol
Authors:
Open Access
- 1 March 2020
- journal article
- research article
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 1, 100012
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (K12HD043488, RO1 5R01HL132985, RO1 P30DK36836)
This publication has 27 references indexed in Scilit:
- PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialThe Lancet, 2015
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant PatientsJAMA, 2012
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 studyThe Lancet, 2012
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 studyThe Lancet, 2012
- Atorvastatin with or without an Antibody to PCSK9 in Primary HypercholesterolemiaNew England Journal of Medicine, 2012
- Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial HypercholesterolemiaCirculation, 2012
- Effects of AMG 145 on Low-Density Lipoprotein Cholesterol LevelsJACC, 2012
- Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trialThe Lancet, 2012
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin TherapyJACC, 2012
- Effect of a Monoclonal Antibody to PCSK9 on LDL CholesterolNew England Journal of Medicine, 2012